Recently, NSCLC patients with driver gene mutation in DDR pathways presented significant higher TMB values and higher objective response rate, longer median PFS after anti-cancer immunotherapy [32].We also found gene alternations for DDR pathway, TP53 pathway, cell cycles pathway and NOTCH pathway apparently happed in high PD-L1 expression patients (P < 0.05), which might provide more evidences for illustrating molecular mechanism involving with PD-L1 expression in NSCLC. The gene discussed is CD274; the disease is cancer.